HENDERSON GLOBAL INVESTORS
Henderson Group is the holding company of the investment management group Henderson Global Investors. Henderson Group's principal place of business is in London and since December 2003 has been listed on the London Stock Exchange and Australian Securities Exchange - appearing in the FTSE 250 and ASX 100 indices. Henderson Group has approximately 40,000 shareholders worldwide. Since 31 October 2008, the Group has been incorporated in Jersey. Established in 1934 to administer the estates of ... Alexander Henderson, the first Lord Faringdon, Henderson Global Investors (Henderson) is a leading independent global asset management firm. The company provides its institutional, retail and high net-worth clients access to skilled investment professionals representing a broad range of asset classes, including equities, fixed income, property and alternative investments. With its principal place of business in London, Henderson is one of Europe's largest investment managers, with £92.7bn assets under management and employs around 1000 people worldwide (as at 31 March 2016). In Europe, Henderson has offices in Amsterdam, Edinburgh, Frankfurt, Luxembourg, Madrid, Milan, Paris, Zurich and London. Henderson has had a presence in North America since 1999, when it acquired US real estate investment manager Phoenix Realty Advisers, and has offices in Boston, Chicago and Philadelphia. In Asia, Henderson has offices in New Delhi, Singapore (Asia headquarters), Hong Kong, Tokyo and Beijing as well as in Sydney, Australia. With investment expertise across every asset class, Henderson's skilful investment managers invest in every major market around the globe. They are supported by a global team of researchers and economists who have a keen understanding of the economic forces driving the security markets and who undertake rigorous sector and theme analysis. Underpinning this process is a comprehensive risk-control framework to ensure that investment views are translated into portfolios managed in line with investors' risk and return requirements.
HENDERSON GLOBAL INVESTORS
Social Links:
Industry:
Finance Financial Services Real Estate Investment
Founded:
1934-01-01
Status:
Active
Contact:
267 238 2700
Technology used in webpage:
IPhone / Mobile Compatible Google Font API Font Awesome Domain Not Resolving Nginx AJAX Libraries API Apple Mobile Web App Capable Amazon S3 CDN IIS 10 Apple Mobile Web App Status Bar Style
Similar Organizations
Cougar Global Investments
Cougar Global Investments is an investment management company.
Eternity Investment
Eternity Investment is an investment company.
Hermes Infrastructure
Hermes Infrastructure is an investment manager.
PALMINA Invest
PALMINA Invest is a global investment consultancy.
Tennor
Tennor is a global investment holding company.
Current Employees Featured
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2011-01-12 | Gartmore Investment Management | Gartmore Investment Management acquired by Henderson Global Investors | N/A |
2009-01-30 | New Star Asset Management | New Star Asset Management acquired by Henderson Global Investors | 115 M GBP |
2004-11-17 | Homann Feinkost | Homann Feinkost acquired by Henderson Global Investors | N/A |
2004-04-07 | Wellnet SpA | Wellnet SpA acquired by Henderson Global Investors | N/A |
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2017-12-15 | Simba Sleep | Henderson Global Investors investment in Series B - Simba Sleep | 40 M GBP |
2017-02-13 | Simba Sleep | Henderson Global Investors investment in Debt Financing - Simba Sleep | 9 M GBP |
2012-02-06 | Verona Pharma | Henderson Global Investors investment in Post-IPO Equity - Verona Pharma | 11.5 M USD |
2008-04-01 | Sharda Cropchem | Henderson Global Investors investment in Private Equity Round - Sharda Cropchem | 1000 M INR |
2007-02-16 | Ziopharm oncology | Henderson Global Investors investment in Post-IPO Equity - Ziopharm oncology | 30.9 M USD |
2006-05-03 | Ziopharm oncology | Henderson Global Investors investment in Post-IPO Equity - Ziopharm oncology | 37 M USD |